EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Efficacy of Non‐Ablative Fractional Laser Combined With Tranexamic Acid in Melasma Treatment: A Randomized Split‐Face Trial

Amirhossein Rahimnia iD, Motahareh Hosnian iD, Amir Houshang Ehsani iD, Pedram Nourmohammadpour iD, Zahra Shadlou, Mina Koohian Mohammadabadi iD, Ala Ehsani iD

Journal of Cosmetic Dermatology · 2025

DOI: 10.1111/jocd.70384 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Cosmetic Dermatology, 2025. Verfasst von Amirhossein Rahimnia und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Razi Hospital, Tehran University of Medical Sciences, Tehran, Iran. Hauptthemen laut MEDLINE: Tranexamic Acid, Melanosis, Lasers, Solid-State, Antifibrinolytic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

The non‐ablative fractionated erbium glass laser (NAFL) 1540 nm combined with topical tranexamic acid (TXA) is a novel therapeutic approach for melasma. However, the efficacy and safety of this combination remain controversial. This study aims to evaluate the effectiveness and safety of NAFL combined with TXA in treating melasma.

Methods

A randomized controlled trial with a split‐face design was conducted on 27 participants with symmetric melasma. All participants applied 5% TXA topically twice daily to their entire face. One side of the face underwent three NAFL sessions combined with TXA at 4‐week intervals, while the opposite side, treated with TXA alone, served as the control. Outcomes were assessed using the modified melasma area and severity index (m‐MASI), physician global assessment (PGA), and participant satisfaction at the end of treatment, and at one and 3 months after the final laser session.

Results

Both facial sides showed significant m‐MASI score improvement at the end of treatment ( p < 0.001); however, a significant recurrence was noted in both groups during follow‐up. The reduction in m‐MASI scores was significantly greater for the NAFL plus TXA group than for TXA alone at the end of treatment ( p = 0.029). However, no significant difference was observed between the groups at the 1‐ and 3‐month follow‐ups ( p = 0.33 and 0.31, respectively). NAFL plus TXA led to significantly better PGA scores at Week 12 ( p < 0.001), but this improvement was not sustained during follow‐up ( p = 0.06 and 0.07, respectively). Participant satisfaction was consistently higher in the NAFL plus TXA group ( p = 0.001).

Conclusions

The combination of NAFL and topical TXA provides significant short‐term clinical benefits in treating melasma, likely by enhancing TXA penetration into target tissues and improving pigmentary clearance. However, its efficacy diminishes over time due to the inevitable recurrence of melasma, necessitating further investigation into long‐term maintenance strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tranexamic AcidMelanosisLasers, Solid-StateAntifibrinolytic AgentsHumansFemaleAdultTreatment OutcomeMiddle AgedCombined Modality TherapyPatient SatisfactionSeverity of Illness IndexMaleAdministration, CutaneousRecurrenceFollow-Up Studies

Stichwörter der Autor:innen

erbium: YAG laserfractional photothermolysismelasmanon‐ablative laserstopical therapy

Substanzen

Tranexamic AcidAntifibrinolytic Agents

Autor:innen und Institutionen

  • Department of Dermatology, Razi Hospital, Tehran University of Medical Sciences, Tehran, Iran.
  • Autoimmune Bullous Diseases Research Center, Razi Hospital, Tehran University of Medical Sciences, Tehran, Iran.
  • School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
  • School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
  • Skin Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
  • Student Research Committee, Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

ORCID-Profile: Amirhossein Rahimnia, Motahareh Hosnian, Amir Houshang Ehsani, Pedram Nourmohammadpour, Mina Koohian Mohammadabadi, Ala Ehsani

Zitieren

APA

Rahimnia, A., Hosnian, M., Ehsani, A. H., Nourmohammadpour, P., Shadlou, Z., Koohian Mohammadabadi, M., & Ehsani, A. (2025). Efficacy of Non‐Ablative Fractional Laser Combined With Tranexamic Acid in Melasma Treatment: A Randomized Split‐Face Trial. Journal of Cosmetic Dermatology. https://doi.org/10.1111/jocd.70384

Vancouver

Rahimnia A, Hosnian M, Ehsani AH, Nourmohammadpour P, Shadlou Z, Koohian Mohammadabadi M, et al. Efficacy of Non‐Ablative Fractional Laser Combined With Tranexamic Acid in Melasma Treatment: A Randomized Split‐Face Trial. Journal of Cosmetic Dermatology. 2025. doi:10.1111/jocd.70384

BibTeX
@article{Rahimnia2025,
  author = {Rahimnia, Amirhossein and Hosnian, Motahareh and Ehsani, Amir Houshang and Nourmohammadpour, Pedram and Shadlou, Zahra and Koohian Mohammadabadi, Mina and Ehsani, Ala},
  title = {Efficacy of Non‐Ablative Fractional Laser Combined With Tranexamic Acid in Melasma Treatment: A Randomized Split‐Face Trial},
  journal = {Journal of Cosmetic Dermatology},
  year = {2025},
  doi = {10.1111/jocd.70384}
}
Kostenlos starten →